Orchard - Unchanged

Health Alert

Health Alert

COVID-19 pandemic is officially over

The COVID-19 public health emergency issued by the federal government expired on May 11, 2023. This means that COVID will be treated like any other disease moving forward:

  • All COVID-19 vaccinations will continue to be covered at 100%.
  • Treatment due to COVID-19 after May 11, 2023, will be covered at regular medical benefits, subject to applicable copays and coinsurance.

COVID-19 Vaccine Information

Vaccines are available at your local health department, certain healthcare providers, and select pharmacies.

The vaccine will cost you nothing. PEHP covers 100% of the cost.

PEHP Coverage of COVID-19 Testing

PEHP covers testing for COVID-19, subject to applicable copays and coinsurance.

  • Call us at (801) 366-7555 to learn more about your benefits.

PEHP Coverage of Medications

PEHP covers FDA authorized or approved treatments for COVID-19. Testing for COVID-19 is covered as a regular benefit subject to cost sharing. Talk to your doctor to see if one of the treatments below is right for you:

Veklury (remdesivir) is approved for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.

Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use)

Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Molnupiravir

Molnupiravir is authorized for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.

Evusheld (tixagevimab co-packaged with cilgavimab)

For emergency use as pre-exposure prophylaxis for prevention of COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

  • Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and
  • Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction.

Actemra (Tocilizumab)

For the treatment of COVID-19 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Sotrovimab

For the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Bamlanivimab and Etesevimab

Bamlanivimab and etesevimab administered together for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

REGEN-COV (Casirivimab and Imdevimab)

Casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Baricitinib (Olumiant)

For emergency use by healthcare providers for the treatment COVID-19 in hospitalized adults and pediatric patients 2 years of age or older requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

COVID-19 convalescent plasma

For the treatment of hospitalized patients with Coronavirus Disease 2019 (COVID-19)

COVID-19 Monoclonal Antibody Therapy

To determine eligibility, use an online risk score calculator or call 1-800-456-7707.